What question did this study set out to answer?

This research aims to evaluate how generalizable AI can distinguish between TROP-2 and cMET phenotypes in non-small cell lung cancer (NSCLC).

April 10, 2026Open Access

ADC target profiling in NSCLC: Generalizable AI separates TROP-2 and cMET phenotypes

Key Points

This research aims to evaluate how generalizable AI can distinguish between TROP-2 and cMET phenotypes in non-small cell lung cancer (NSCLC).
Utilized foundation model-based scoring for biomarker quantification.
Analyzed TME phenotypes to categorize as TROP-2-high immune-deserted and cMET-high immune-active.
Evaluated therapeutic implications of identified phenotypes.
AI effectively distinguished TROP-2 and cMET phenotypes in NSCLC.
Identified therapeutic combinations involving ADCs and immunotherapies or kinase inhibitors.
Results demonstrate significant variability in immune activity between the two phenotypes.

Abstract

Foundation model-based scoring produces expert-level, scalable biomarker quantification. The resulting TME phenotypes - TROP-2-high immune-deserted vs cMET-high, immune-active - reveal therapeutic implications for combining ADCs with immunotherapies or kinase inhibitors.

ADC target profiling in NSCLC: Generalizable AI separates TROP-2 and cMET phenotypes

Key Points

Abstract

Cite This Study

Also Consider

Also Consider